Expression of secretory phospholipase A2s in human atherosclerosis development


      Secretory phospholipase A2s (sPLA2s) contribute to the hydrolysis of phospholipid. Among them, sPLA2-IIA, -V, and -X have been regarded as enhancers of lipid accumulation in arterial intima. However, the distribution and production of the other types of sPLA2 in human aortic wall remain unclear. Therefore, in this study, the distribution and production of seven types of sPLA2 including IIA, IID, IIE, IIF, III, V, and X in atherosclerosis development in the human aorta were comprehensively examined by immunohistochemistry and in situ hybridization (ISH). The extent of sPLA2s expression increased with atherosclerosis development, but only sPLA2-IIF was never observed in the normal aorta. Double-immunostaining demonstrated that sPLA2-V expression was limited to smooth muscle cells (SMCs), although the other sPLA2s were expressed in both macrophages and SMCs. ISH using sPLA2 cDNAs revealed that the expression pattern of each mRNA was consistent with the results of immunohistochemistry for each corresponding sPLA2. These results indicate that the seven types of sPLA2 are expressed with various patterns in all stages of atherosclerosis development and may play an atherogenic role through degradation of phospholipid.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ross R.
        The pathogenesis of atherosclerosis—an update.
        N Engl J Med. 1986; 314: 488-500
        • Stary H.C.
        Atlas of atherosclerosis: progression and regression.
        Parthenon Publishing, New York1999 (p. 10–28)
        • Camejo G.
        • Hurt-Camejo E.
        • Wiklund O.
        • Bondjers G.
        Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis.
        Atherosclerosis. 1998; 139: 205-222
        • Ishikawa Y.
        • Ishii T.
        • Akasaka Y.
        • Masuda T.
        • Strong J.P.
        • Zieske A.W.
        • et al.
        Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study.
        Atherosclerosis. 2001; 158: 215-225
        • Ishikawa Y.
        • Akasaka Y.
        • Ishii T.
        • Komiyama K.
        • Masuda S.
        • Asuwa N
        • et al.
        Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta.
        Arterioscler Thromb Vasc Biol. 1998; 18: 665-672
        • Ishikawa Y.
        • Ito K.
        • Akasaka Y.
        • Ishii T.
        • Masuda T.
        • Zhang L.
        • et al.
        The distribution and production of cholesteryl ester transfer protein in the human aortic wall.
        Atherosclerosis. 2001; 156: 29-37
        • Gelissen I.C.
        • Hochgrebe T.
        • Wilson M.R.
        • Easterbrook-Smith S.B.
        • Jessup W.
        • Dean R.T.
        • et al.
        Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?.
        Biochem J. 1998; 331: 231-237
        • Morton R.E.
        Interaction of plasma-derived lipid transfer protein with macrophages in culture.
        J Lipid Res. 1988; 29: 1367-1377
        • Curtiss L.K.
        • Boisvert W.A.
        Apolipoprotein E and atherosclerosis.
        Curr Opin Lipidol. 2000; 11: 243-251
        • Singer A.G.
        • Ghomashchi F.
        • Le Calvez C.
        • Bollinger J.
        • Bezzine S.
        • Rouault M.
        • et al.
        Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.
        J Biol Chem. 2002; 277: 48535-48549
        • Murakami M.
        • Masuda S.
        • Shimbara S.
        • Ishikawa Y.
        • Ishii T.
        • Kudo I.
        Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2.
        J Biol Chem. 2005; 280: 24987-24998
        • Schönbeck U.
        • Sukhova G.K.
        • Graber P.
        • Coulter S.
        • Libby P.
        Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.
        Am J Pathol. 1999; 155: 1281-1291
        • Ivandic B.
        • Castellani L.W.
        • Wang X.P.
        • Qiao J.H.
        • Mehrabian M.
        • Navab M.
        • et al.
        Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1284-1290
        • Hakala J.K.
        • Oörni K.
        • Pentikäinen M.O.
        • Hurt-Camejo E.
        • Kovanen P.T.
        Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1053-1058
        • Sartipy P.
        • Johansen B.
        • Gâsvik K.
        • Hurt-Camejo E.
        Molecular basis for the association of group IIA phospholipase A (2) and decorin in human atherosclerotic lesions.
        Circ Res. 2000; 86: 707-714
        • Wooton-Kee C.R.
        • Boyanovsky B.B.
        • Nasser M.S.
        • de Villiers W.J.
        • Webb N.R.
        Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.
        Arterioscler Thromb Vasc Biol. 2004; 24: 762-767
        • Hanasaki K.
        • Yamada K.
        • Yamamoto S.
        • Ishimoto Y.
        • Saiga A.
        • Ono T.
        • et al.
        Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
        J Biol Chem. 2002; 277: 29116-29124
        • Ishimoto Y.
        • Yamada K.
        • Yamamoto S.
        • Ono T.
        • Notoya M.
        • Hanasaki K.
        Group V and X secretory phospholipase A (2) s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions.
        Biochim Biophys Acta. 2003; 1642: 129-138
        • Kohno M.
        • Yokokawa K.
        • Yasunari K.
        • Minami M.
        • Kano H.
        • Hanehira T.
        • et al.
        Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration.
        Circulation. 1998; 98: 353-359
        • Degousee N.
        • Ghomashchi F.
        • Stefanski E.
        • Singer A.
        • Smart B.P.
        • Borregaard N.
        • et al.
        Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis.
        J Biol Chem. 2002; 277: 5061-5073
        • Masuda S.
        • Murakami M.
        • Mitsuishi M.
        • Komiyama K.
        • Ishikawa Y.
        • Ishii T.
        • et al.
        Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells.
        Biochem J. 2005; 387: 27-38
        • Masuda S.
        • Murakami M.
        • Komiyama K.
        • Ishihara M.
        • Ishikawa Y.
        • Ishii T.
        • et al.
        Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells.
        FEBS J. 2005; 272: 655-672
        • Masuda S.
        • Murakami M.
        • Ishikawa Y.
        • Ishii T.
        • Kudo I.
        Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues.
        Biochim Biophys Acta. 2005; 1736: 200-210
        • Ishikawa Y.
        • Komiyama K.
        • Masuda S.
        • Murakami M.
        • Akasaka Y.
        • Ito K.
        • et al.
        Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
        Histopathology. 2005; 47: 257-267
        • Murakami M.
        • Kudo I.
        New phospholipase A(2) isozymes with a potential role in atherosclerosis.
        Curr Opin Lipidol. 2003; 14: 431-436
        • Balboa M.A.
        • Balsinde J.
        • Winstead M.V.
        • Tischfield J.A.
        • Dennis E.A.
        Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
        J Biol Chem. 1996; 271: 32381-32384
        • Satake Y.
        • Diaz B.L.
        • Balestrieri B.
        • Lam B.K.
        • Kanaoka Y
        • Grusby M.J.
        • et al.
        Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption.
        J Biol Chem. 2004; 279: 16488-16494
        • Menschikowski M.
        • Rosner-Schiering A.
        • Eckey R.
        • Mueller E.
        • Koch R.
        • Jaross W.
        Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues.
        Arterioscler Thromb Vasc Biol. 2000; 20: 751-762
        • O’Brien K.D.
        • Vuletic S.
        • McDonald T.O.
        • Wolfbauer G.
        • Lewis K.
        • Tu A.Y.
        • et al.
        Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis.
        Circulation. 2003; 108: 270-274
        • Miyazaki A.
        • Sakashita N.
        • Lee O.
        • Takahashi K.
        • Horiuchi S.
        • Hakamata H.
        • et al.
        Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1568-1574
        • Anthonsen M.W.
        • Stengel D.
        • Hourton D.
        • Ninio E.
        • Johansen B.
        Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1276-1282
        • Linton M.F.
        • Fazio S.
        Cyclooxygenase-2 and inflammation in atherosclerosis.
        Curr Opin Pharmacol. 2004; 4: 116-123